Seneca Valley virus-001

Phase 1Biologic

CChildren's Oncology Group

Seneca Valley virus-001 is one of 24 biologic programs targeting Neuroendocrine Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine CarcinomaRecruiting

Neuroendocrine CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

25 competitors in Neuroendocrine Carcinoma

#DrugCompanyPhaseTrials

Eloxatin

Lenvima

Sandostatin

Kyprolis

VVirionyx Corporation Limited

Tarlatamab-Dznl

2 6

Tecentriq

Roche

Phase 2

2 7

Opdivo

Bristol-Myers Squibb

Phase 2

2 8

Imfinzi

AstraZeneca

Phase 2

2 9

Yervoy

Bristol-Myers Squibb

Phase 2

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

Neuroendocrine Carcinoma

NCT06889493

Clinical

Trials by Indication[1]

Rhabdomyosarcoma1 trial

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Completed·CChildren's Oncology Group·Phase 1·NCT01048892·22 enrolled

Small Cell Lung Cancer1 trial

Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01017601·59 enrolled

Neuroendocrine Carcinoma1 trial

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Recruiting·PPeter Hosein, MD·Phase 1·NCT06889493·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Seneca Valley virus-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Seneca Valley virus-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Seneca Valley virus-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CChildren's Oncology Group

Seneca Valley virus-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Rhabdomyosarcoma1 trial

Small Cell Lung Cancer1 trial

Neuroendocrine Carcinoma1 trial

References

Drug Info

Quick Facts

Related News